Venus Remedies Limited (BOM:526953)
India · Delayed Price · Currency is INR 726.40
-20.60 (-2.76%)
At close: Jan 23, 2026
Venus Remedies Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
Operating Revenue | 6,991 | 6,479 | 6,014 | 5,555 | 6,002 | 5,481 | Upgrade |
Other Revenue | 0.1 | - | - | - | - | - | Upgrade |
| 6,991 | 6,479 | 6,014 | 5,555 | 6,002 | 5,481 | Upgrade | |
Revenue Growth (YoY) | 13.74% | 7.72% | 8.27% | -7.44% | 9.50% | 60.90% | Upgrade |
Cost of Revenue | 3,962 | 3,801 | 3,564 | 3,329 | 3,870 | 3,408 | Upgrade |
Gross Profit | 3,029 | 2,678 | 2,451 | 2,226 | 2,132 | 2,073 | Upgrade |
Selling, General & Admin | 1,948 | 1,862 | 1,697 | 1,397 | 1,281 | 1,378 | Upgrade |
Research & Development | 170.65 | 180.85 | 158.4 | 228.85 | 230.3 | 157.58 | Upgrade |
Other Operating Expenses | -89.82 | -89.82 | -5.08 | -4.86 | -4.63 | -7.8 | Upgrade |
Operating Expenses | 2,254 | 2,178 | 2,114 | 1,944 | 1,842 | 1,880 | Upgrade |
Operating Income | 775.45 | 500.05 | 336.65 | 282.13 | 290.43 | 192.81 | Upgrade |
Interest Expense | -0.45 | -0.65 | -0.94 | -1.18 | -3.03 | -70.1 | Upgrade |
Interest & Investment Income | 45.42 | 45.42 | 41.66 | 18.99 | 8.16 | 1.22 | Upgrade |
Currency Exchange Gain (Loss) | 50.07 | 50.07 | 59.54 | 73.24 | 64.15 | 64.95 | Upgrade |
Other Non Operating Income (Expenses) | -35.93 | 7.97 | 4.01 | 6.04 | 4.37 | 62.24 | Upgrade |
EBT Excluding Unusual Items | 834.55 | 602.85 | 440.92 | 379.22 | 364.08 | 251.11 | Upgrade |
Gain (Loss) on Sale of Investments | 16.28 | 16.28 | 5.51 | 0.08 | - | - | Upgrade |
Other Unusual Items | 99.13 | 99.13 | - | - | - | 234.42 | Upgrade |
Pretax Income | 949.97 | 718.27 | 446.43 | 379.3 | 364.08 | 485.53 | Upgrade |
Income Tax Expense | 246.92 | 265.12 | 161.53 | 113.65 | -43.16 | -132.12 | Upgrade |
Net Income | 703.05 | 453.15 | 284.91 | 265.66 | 407.24 | 617.65 | Upgrade |
Net Income to Common | 703.05 | 453.15 | 284.91 | 265.66 | 407.24 | 617.65 | Upgrade |
Net Income Growth | 217.97% | 59.05% | 7.25% | -34.77% | -34.07% | - | Upgrade |
Shares Outstanding (Basic) | 13 | 13 | 13 | 13 | 13 | 12 | Upgrade |
Shares Outstanding (Diluted) | 13 | 13 | 13 | 13 | 13 | 12 | Upgrade |
Shares Change (YoY) | -0.17% | - | - | 1.30% | 6.92% | - | Upgrade |
EPS (Basic) | 52.64 | 33.90 | 21.31 | 19.87 | 30.86 | 50.04 | Upgrade |
EPS (Diluted) | 52.64 | 33.90 | 21.31 | 19.87 | 30.86 | 50.04 | Upgrade |
EPS Growth | 218.60% | 59.08% | 7.22% | -35.60% | -38.33% | - | Upgrade |
Free Cash Flow | 1,225 | 768.15 | 279.67 | 288.09 | 273.94 | 1,241 | Upgrade |
Free Cash Flow Per Share | 91.69 | 57.47 | 20.92 | 21.55 | 20.76 | 100.56 | Upgrade |
Gross Margin | 43.33% | 41.34% | 40.75% | 40.07% | 35.52% | 37.83% | Upgrade |
Operating Margin | 11.09% | 7.72% | 5.60% | 5.08% | 4.84% | 3.52% | Upgrade |
Profit Margin | 10.06% | 6.99% | 4.74% | 4.78% | 6.78% | 11.27% | Upgrade |
Free Cash Flow Margin | 17.52% | 11.86% | 4.65% | 5.19% | 4.56% | 22.64% | Upgrade |
EBITDA | 971.11 | 696.01 | 601.08 | 605.1 | 625.77 | 545.57 | Upgrade |
EBITDA Margin | 13.89% | 10.74% | 9.99% | 10.89% | 10.43% | 9.95% | Upgrade |
D&A For EBITDA | 195.66 | 195.96 | 264.43 | 322.98 | 335.34 | 352.76 | Upgrade |
EBIT | 775.45 | 500.05 | 336.65 | 282.13 | 290.43 | 192.81 | Upgrade |
EBIT Margin | 11.09% | 7.72% | 5.60% | 5.08% | 4.84% | 3.52% | Upgrade |
Effective Tax Rate | 25.99% | 36.91% | 36.18% | 29.96% | - | - | Upgrade |
Revenue as Reported | 7,157 | 6,688 | 6,130 | 5,658 | 6,085 | 5,678 | Upgrade |
Advertising Expenses | - | 104.31 | 132.54 | 84.83 | 44.26 | 25.75 | Upgrade |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.